AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology. Molecular glue degraders are a novel class of small molecules that are designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation, offering a more precise approach to treatment. Molecular glue degraders have the potential to target proteins that have historically been defined as “undruggable”. Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64B in aggregate option fees and milestones, as well as tiered royalties on net sales.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards
- Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- AbbVie price target lowered to $212 from $221 at Guggenheim